Orforglipron compared with dulaglutide in children and teens with type 2 diabetes
Compares orforglipron with dulaglutide in young people who have type 2 diabetes.
Plain-language title generated from the registry record
Registry title: A Study of Orforglipron (LY3502970) Compared With Dulaglutide in Pediatric Participants With Type 2 Diabetes
Key facts
- Where
- Ammon, Atlanta, Beaumont, Corpus Christi, Decatur, Edinburg, Nashville, Sacramento, San Diego, Shavano Park, Smithfield, Stamford, Syracuse, The Bronx, Topeka, Tulsa, and Victoria, United StatesSee the 17 sites
- Phase
- Phase 3
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 10 and 17 years old?
Source: NCT07668336, who can take part
Where in United States
- Medical Research PartnersAmmon, United StatesTaking people
- Children's Healthcare of Atlanta - Center for Advanced Pediatrics (CAP)Atlanta, United StatesNot yet recruiting
- Gadolin ResearchBeaumont, United StatesTaking people
- Driscoll Children's HospitalCorpus Christi, United StatesTaking people
- CenExel iResearch, LLCDecatur, United StatesTaking people
- Proactive Clinical Research LLCEdinburg, United StatesTaking people
- Vanderbilt Health One Hundred OaksNashville, United StatesNot yet recruiting
- Sutter Valley Medical Foundation (SVMF) Pediatric EndocrinologySacramento, United StatesTaking people
- Rady Children's HospitalSan Diego, United StatesNot yet recruiting
- Consano Clinical Research, LLCShavano Park, United StatesTaking people
- Frontier Clinical Research, LLCSmithfield, United StatesTaking people
- Stamford Therapeutics ConsortiumStamford, United StatesTaking people
- SUNY Upstate Medical UniversitySyracuse, United StatesNot yet recruiting
- Advantage Clinical TrialsThe Bronx, United StatesTaking people
- Cotton O'Neil Diabetes & EndocrinologyTopeka, United StatesTaking people
- Central States ResearchTulsa, United StatesTaking people
- Victoria Clinical Research GroupVictoria, United StatesTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Eli Lilly and Company
- Trial code
- NCT07668336EU 2025-524811-35-00
- Record updated
- 5 November 2026
- Original description
This study looks at how well a medicine called orforglipron works compared to another medicine called dulaglutide in pediatric participants aged 10 to less than 18 years with type 2 diabetes. The study will also check how safe these medicines are and how the body processes them.Read full original descriptionShow less
A Phase 3, Randomized, Open-Label Study to Investigate the Efficacy, Safety, and Pharmacokinetics of Once-Daily Oral Orforglipron Compared With Once-Weekly Dulaglutide in Pediatric Participants 10 to Less Than 18 Years of Age With Type 2 Diabetes
This study looks at how well a medicine called orforglipron works compared to another medicine called dulaglutide in pediatric participants aged 10 to less than 18 years with type 2 diabetes. The study will also check how safe these medicines are and how the body processes them.
Participation in the study will last about 61 weeks.
Inclusion: Have type 2 diabetes treated with diet and exercise and metformin and/or basal insulin; Have HbA1c > 6.5% to ≤ 11.0% at screening; Have a body weight ≥50 kilograms (kg) (110 pounds) and a body mass index (BMI) of >85th percentile.
Exclusion: Have had at least one episode of severe hypoglycemia and/or at least one episode of hypoglycemic unawareness within the last 6 months before screening; Have been treated with prescription drugs or over-the-counter medications that promote weight loss within 90 days prior to screening; Have type 1 diabetes; After the type 2 diabetes diagnosis, have a history of diabetic ketoacidosis or hyperosmolar syndrome; Have a history of pancreatitis or gallbladder disease; Have a personal or family history of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia syndrome type 2 (MEN2); Have received treatment with any glucose-lowering agent(s) other than metformin, basal insulin, or (SGLT2) inhibitors within 90 days prior to screening.